MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: Placebo
First Posted Date
2009-12-10
Last Posted Date
2017-03-07
Lead Sponsor
Pfizer
Target Recruit Count
145
Registration Number
NCT01029405

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Phase 1
Terminated
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2009-12-09
Last Posted Date
2014-06-04
Lead Sponsor
Pfizer
Target Recruit Count
9
Registration Number
NCT01028911
Locations
🇺🇸

Pfizer Investigational Site, Wichita, Kansas, United States

Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

Phase 3
Completed
Conditions
13-valent Pneumococcal Vaccine
Immunization
Safety
Antibody Response
Interventions
Biological: 13-valent pneumococcal conjugate vaccine
First Posted Date
2009-12-04
Last Posted Date
2012-02-08
Lead Sponsor
Pfizer
Target Recruit Count
263
Registration Number
NCT01026038
Locations
🇫🇷

Pfizer Investigational Site, Vitry Sur Seine, France

Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects

Phase 1
Completed
Conditions
Respiratory Tract Infections
Interventions
Drug: Placebo
First Posted Date
2009-12-04
Last Posted Date
2011-05-04
Lead Sponsor
Pfizer
Target Recruit Count
39
Registration Number
NCT01026545
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated

Phase 3
Completed
Conditions
Healthy
Interventions
Other: Blood draw
First Posted Date
2009-12-03
Last Posted Date
2012-06-20
Lead Sponsor
Pfizer
Target Recruit Count
962
Registration Number
NCT01025336
Locations
🇺🇸

Pfizer Investigational Site, Seattle, Washington, United States

A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers

Phase 1
Completed
Conditions
Arthritis, Rheumatoid
Interventions
First Posted Date
2009-12-02
Last Posted Date
2010-06-16
Lead Sponsor
Pfizer
Target Recruit Count
5
Registration Number
NCT01023100
Locations
🇺🇸

Pfizer Investigational Site, Woburn, Massachusetts, United States

A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2009-11-25
Last Posted Date
2010-04-22
Lead Sponsor
Pfizer
Target Recruit Count
42
Registration Number
NCT01020136
Locations
🇸🇬

Pfizer Investigational Site, Singapore, Singapore

An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Phase 1
Completed
Conditions
Bacterial Infections
Immunotherapy, Active
Staphylococcal Infections
Staphylococcal Skin Infections
Staphylococcal Vaccines
Interventions
Biological: SA3Ag vaccine
Biological: SA3Ag followed by Placebo
Biological: Placebo
Biological: SA3Ag with no booster in stage 2
Procedure: Placebo with no booster in stage 2
Procedure: Blood draw
Procedure: Colonization swab samples
First Posted Date
2009-11-23
Last Posted Date
2014-04-24
Lead Sponsor
Pfizer
Target Recruit Count
449
Registration Number
NCT01018641
Locations
🇦🇺

Pfizer Investigational Site, Subiaco, Western Australia, Australia

Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption

Phase 1
Withdrawn
Conditions
Healthy Volunteers
Interventions
First Posted Date
2009-11-23
Last Posted Date
2016-04-06
Lead Sponsor
Pfizer
Registration Number
NCT01017926

Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections

Phase 1
Completed
Conditions
Gram-negative Bacterial Infection
Interventions
Drug: Placebo
First Posted Date
2009-11-17
Last Posted Date
2019-03-05
Lead Sponsor
Pfizer
Target Recruit Count
64
Registration Number
NCT01015014
Locations
🇦🇺

CMAX, Adelaide, Australia

© Copyright 2025. All Rights Reserved by MedPath